Vaccines and Vaccine Delivery Systems: Experience with HSV, Influenza and Mucosal Routes of Immunisation
The primary route of entry into the body for many viruses, including herpes simplex virus type 2 (HSV-2) and the influenza virus, is via mucosal surfaces. It follows that, depending on the numbers of virions deposited on such surfaces, their infectious quality and distribution over the mucosal surface, the existence or early mobilisation of specific defence mechanisms at the time of this contact, supplementing or enhancing any non-specific resistance mechanisms already operating at these sites may tip the balance in favour of the host and result in elimination of the invading virus before it can become established in the tissues and produce disease symptoms.
KeywordsInfluenza Virus Mucosal Surface Genital Herpes Influenza Virus Vaccine Vaccine Delivery System
Unable to display preview. Download preview PDF.
- Eis-Hubinger, A.M., Schmidt, D.S. and Schneweis, K.E., 1993, Anti-glycoprotein B mono-clonal antibody protects T-cell depleted mice against herpes simplex virus infection by inhibition of virus replication at the inoculated mucous membranes. Journal of General Virology, 74, 379–385.PubMedCrossRefGoogle Scholar
- Ghazi, H.O., Potter, C.W., Smith, T.L. and Jennings, R., 1995a, Comparative antibody responses and protection in mice immunised by oral or parenteral routes with influenza virus subunit antigens in aqueous form or incorporated into ISCOMs. Journal of Medical Microbiology, 42, 53.PubMedCrossRefGoogle Scholar
- Hassan, Y., Brewer, J.M., Alexander, J. and Jennings, R., 1996, Immune responses in mice induced by HSV-1 glycoprotein presented with ISCOMs or NISV delivery systems. Vaccine, In press.Google Scholar
- Hazama, M., Mayumi-Aono, A., Miyazaki, T., Hinuma, S. and Fujisawa, Y., 1993, Intranasal immunisation against herpes simplex virus infection by using a recombinant glyco-protein D fused with immuno-modulating proteins, the B subunit of Escherichia coli heat-labile enterotoxin and interleukin-2. Immunology, 78, 643.PubMedGoogle Scholar
- McLean, C.S., Erturk, M., Jennings, R., Ni Challanain, D., Minson, A.C., Duncan, I. Bournsell, M.E.G. and Inglis, S.C., 1994, Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1. Journal of Infectious Diseases, 170, 100.CrossRefGoogle Scholar
- Mowat, A.McI., Maloy, K.J. and Donachie, A.M., 1993, Immune stimulating complexes (ISCOMs) are unique adjuvants for oral immunisation with protein antigens. Immunology, 80, 661.Google Scholar
- Renegar, K.B. and Small, P.A. Jr., 1991, Passive transfer of local immunity to influenza virus infections by IgA antibody. Journal of Immunology, 146, 1972.Google Scholar
- Roitt, I., Brostoff, J. and Male, D., eds., 1996, Vaccination, In: “Immunology”, Chapter 19; p. 191. 4th Edition, Published by Mosby.Google Scholar